Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07211542) titled 'A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis' on Sept. 30.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Condition:
Moderate-to-severe Atopic Dermatitis
Intervention:
Drug: SHR-1905 Injection
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: November 2025
Target Sample Size: 20
Countri...